Sertraline and Appetite/Weight Effects

Safety and Tolerability

Sertraline is regarded as well‑tolerated in patients with Alzheimer’s disease, and guideline statements do not list appetite stimulation or weight gain as characteristic side effects (moderate‑strength guideline evidence) 1.

Sertraline can produce mild, bidirectional changes in appetite (either increase or decrease) that generally emerge within the first few weeks of therapy; overall weight change is minimal, indicating a largely weight‑neutral profile (clinical evidence) 2.

Regular weight monitoring is recommended during sertraline treatment because individual responses vary, and some patients may experience early‑phase appetite changes in either direction (clinical recommendation) 2.

Mirtazapine is specifically noted to promote sleep, increase appetite, and cause weight gain (moderate‑strength guideline evidence) 3

Within the SSRI class, paroxetine has consistently shown the highest risk of weight gain, while sertraline typically causes minimal weight changes 4
Bupropion is the only antidepressant consistently shown to promote weight loss through appetite suppression 4
The American College of Physicians notes that sertraline has been studied for weight effects, but the evidence was limited to one small study with non-statistically significant results at the time of their guideline development 5, 6

For patients with significant concerns about weight gain, bupropion may be a better alternative as it consistently shows the least weight gain or even weight loss 4
Regular weight monitoring is recommended during sertraline treatment, as individual responses may vary despite the generally minimal average weight changes 7